Oncoinvent ASA
Oslo Stock ExchangeTotal Valuation
Oncoinvent ASA carries a market capitalization of 230.19M, placing it among publicly traded companies globally. Its enterprise value stands at 325.84M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 230.19M |
| Enterprise Value | 325.84M |
Share Statistics
Oncoinvent ASA currently has 609,941.00 shares outstanding.
| Shares Outstanding | 609,941.00 |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 530.34, and the price-to-book ratio stands at -0.72.
| PE Ratio | N/A |
| PS Ratio | 530.34 |
| PB Ratio | -0.72 |
| P/TBV Ratio | 4.15 |
| P/FCF Ratio | -2.93 |
| P/OCF Ratio | -2.93 |
Enterprise Valuation
| EV / Sales | 384.24 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Oncoinvent ASA maintains a current ratio of 2.46, meaning it holds 2.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 6.88, indicating elevated leverage, while an interest coverage ratio of -32.18 demonstrates limited ability to service its debt obligations.
| Current Ratio | 2.46 |
| Quick Ratio | 2.27 |
| Debt / Equity | 6.88 |
| Debt / EBITDA | -0.05 |
| Interest Coverage | -32.18 |
Financial Efficiency
| Return on Equity (ROE) | -465.89 |
| Return on Assets (ROA) | -80.66 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Oncoinvent ASA's stock has declined approximately -60.46154% over the past 52 weeks. The 50-day moving average sits at 47.07, while the 200-day moving average is 52.78.
| Beta (5Y) | N/A |
| 52-Week Price Change | -60.46154% |
| 50-Day Moving Average | 47.07 |
| 200-Day Moving Average | 52.78 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Oncoinvent ASA generated 848,000.00 in revenue and converted that into -139.28M in net income, yielding earnings per share of -253.33. EBITDA reached -151.23M, while operating income came in at -151.23M.
| Revenue | 848,000.00 |
| Gross Profit | N/A |
| Operating Income | -151.23M |
| Pretax Income | -139.28M |
| Net Income | -139.28M |
| EBITDA | -151.23M |
| EBIT | -151.23M |
| Earnings Per Share (EPS) | -253.33 |
Balance Sheet
Oncoinvent ASA holds 131.35M in cash and equivalents against 7.45M in total debt, resulting in a net debt position of -130.53M. Total book value stands at -627.54M, with working capital of 84.34M providing operational flexibility.
| Cash & Cash Equivalents | 131.35M |
| Total Debt | 7.45M |
| Net Debt | -130.53M |
| Equity (Book Value) | -627.54M |
| Book Value Per Share | -1,141.41 |
| Working Capital | 84.34M |
Cash Flow
Oncoinvent ASA produced -153.24M in operating cash flow over the past twelve months.
| Operating Cash Flow | -153.24M |
| Capital Expenditures | N/A |
| Free Cash Flow | -153.24M |
| FCF Per Share | -278.72 |
Margins
Oncoinvent ASA operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -17,833.73 and net profit margin of -16,424.65 provide insight into operational efficiency.
| Gross Margin | 100.00 |
| Operating Margin | -17,833.73 |
| Pretax Margin | -16,424.65 |
| Profit Margin | -16,424.65 |
| EBITDA Margin | -17,833.73 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -28.82 |
| FCF Yield | -34.07 |
Stock Splits
Oncoinvent ASA's most recent stock split took place on January 19, 2026 with a 100:1 split ratio.
| Last Split Date | 1/19/2026 |
| Split Ratio | 100:1 |
Scores
Oncoinvent ASA posts an Altman Z-Score of -3.23, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -3.23 |